Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy
Open Access
- 4 November 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e042488
Abstract
Background: Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy. Methods: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified. Results: We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55–73]). Patients were followed for a median of 3037.0 days (IQR, 2808–3221) before mavacamten initiation and for 240 days (IQR, 117–407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new‐onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow‐up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n=80, 26%), AF (n=74, 24%), and AFL (n=16, 5%)). Predictors of outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack/stroke claim) were age at mavacamten start, obesity, transient ischemic attack/stroke history, and residence in the Western versus Southern United States. Conclusions: Over an 8‐month median follow‐up on mavacamten in patients with obstructive hypertrophic cardiomyopathy, new AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to better understand the expected incidence of AF/AFL, HF, and other long‐term outcomes of mavacamten treatment in obstructive hypertrophic cardiomyopathy.Keywords
This publication has 25 references indexed in Scilit:
- Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic CardiomyopathyJACC: Clinical Electrophysiology, 2024
- Atrial Fibrillation in Hypertrophic CardiomyopathyJACC: Advances, 2024
- Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with MavacamtenHeart Rhythm, 2024
- Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With MavacamtenJACC: Heart Failure, 2024
- The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic CardiomyopathyCanadian Journal of Cardiology, 2024
- Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United StatesThe American Journal of Cardiology, 2023
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyJACC, 2022
- Mavacamten depresses human atrial contractility in the same EC50% range as human ventricleBiophysical Journal, 2022
- Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US populationAmerican Heart Journal Plus: Cardiology Research and Practice, 2022
- Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2021